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Abstract
Current radiological emergency response recommendations have been provided by the International Commission on Radiologi-
cal Protection and adopted by the International Atomic Energy Agency in comprehensive Safety Standards. These standards 
provide dose-based guidance for decision making (e.g., on sheltering or relocation) via generic criteria in terms of effective 
dose in the range from 20 mSv per year, during transition from emergency to existing exposure situation, to 100 mSv, acute 
or annual, in the urgent phase of a nuclear accident. The purpose of this paper was to examine how such dose reference levels 
directly translate into radiation-related risks of the main stochastic detrimental health effects (cancer). Methodologies, provided 
by the World Health Organization after the Fukushima accident, for calculating the lifetime and 20 year cancer risks and for 
attributing relevant organ doses from effective doses, have been applied here for this purpose with new software, designed to 
be available for use immediately after a nuclear accident. A new feature in this software is a comprehensive accounting for 
uncertainty via simulation technique, so that the risks may now be presented with realistic confidence intervals. The types of 
cancer risks considered here are time-integrated over lifetime and the first 20 years after exposure for all solid cancers and 
either the most radiation-sensitive types of cancer, i.e., leukaemia and female breast cancer, or the most radiation-relevant 
type of cancer occurring early in life, i.e., thyroid. It is demonstrated here how reference dose levels translate differently into 
specific cancer risk levels (with varying confidence interval sizes), depending on age at exposure, gender, time-frame at-risk 
and type of cancer considered. This demonstration applies German population data and considers external exposures. Further 
work is required to comprehensively extend this methodology to internal exposures that are likely to be important in the early 
stages of a nuclear accident. A discussion is provided here on the potential for such risk-based information to be used by 
decision makers, in the urgent and transition phases of nuclear emergencies, to identify protective measures (e.g., sheltering, 
evacuation) in a differential way (i.e., for particularly susceptible sub-groups of a population).
Keywords Nuclear accidents · Health risk assessment · Radiological emergency response · Radiation protection · Lifetime 
risk
Introduction
The existing system of radiation protection, based on the 
International Commission on Radiological Protection 
(ICRP) 2007 Recommendations (ICRP 2007) and speci-
fied in the International Atomic Energy Agency (IAEA) 
system of safety standards, requirements and guides (IAEA 
2006, 2014, 2015), addresses requirements for protection 
in planned or existing exposure situations or in cases of 
nuclear or radiological incidents and emergencies. Protec-
tion actions following the emergencies can be attributed to 
two phases: an emergency or urgent phase during or imme-
diately following the incident, which is characterised by a 
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quickly varying situations and radiological dangers to be 
addressed, and a longer phase of transition to an existing 
exposure situation when the situation is under control. Dur-
ing the urgent and transition phases of a nuclear emergency, 
important decisions on implementing measures aimed at 
protecting affected populations, such as sheltering or reloca-
tion, need to be made quickly, effectively and incisively. The 
IAEA Safety Standards, including principles, requirements 
and guidelines, provide a uniform, internationally accepted, 
framework to implement protective and mitigating actions. 
The IAEA generic criteria for planning emergency response 
actions are typically formulated using constraints and limits 
defined using dosimetric bases as ranges of effective dose 
(IAEA 2015, 2016). The IAEA requirements, based on pub-
lications from the ICRP (2007), suggest a typical band of 
effective dose from 20 to 100 mSv to be used for planning in 
the emergency situation. The IAEA requirements provide a 
common framework for the Member States to develop their 
own national legislations on radiation protection, including 
norms and limits.
Constraints and limits are not necessarily to be defined 
in terms of dose units. Alternatively, they can be formulated 
as risk constraints, i.e., risks associated with radiological 
dangers (see, e.g., IAEA 2016). The aim of this paper was 
to demonstrate that, in taking decisions aimed at protecting 
affected populations from the main stochastic effects (can-
cer), risk bases can complement dosimetric bases in the 
decision making process.
Unfortunately, in the past, cancer risk assessment soft-
ware was not designed to be available for use immediately 
after a nuclear accident. After the Fukushima nuclear acci-
dent on 11th March 2011 (Wakeford 2011), for example, 
there was a time interval of just under 2 years between acci-
dent occurrence and the publication of the World Health 
Organization (WHO) health risk assessment (WHO 2013) 
report. This long-time interval was due to the work-load, 
after the event, in assessing doses, developing a risk assess-
ment framework and developing the risk assessment soft-
ware (and that was without a full explicit mathematical treat-
ment of risk uncertainties). In order to close such potential 
future time gaps between accidents and health risk assess-
ments, by implementing lessons learned after Fukushima 
(Walsh 2016), the European Union-CONFIDENCE (Cop-
ing with uncertainty for improved modelling and decision 
making in nuclear emergencies) project provided funding to 
develop a risk assessment software (the EU-CONFIDENCE 
software tool) designed to be immediately available after 
a nuclear accident. The tool encompasses the risk assess-
ment methodological framework for assessing cancer risks 
after the Fukushima accident as suggested by a WHO expert 
group (WHO 2013; Walsh et al. 2014) and by the German 
software tool ProZES (Jacob et al., 2017; Ulanowski et al. 
2016).
The WHO methodology has been applied to: (a) trans-
late the effective dose limits to the organ doses that are 
relevant for radiation risk assessment; and (b) to calcu-
late risk of all solid, breast, thyroid cancers and leukae-
mia using these converted organ dose and contemporary 
models of radiation risk for an illustrative modern Euro-
pean population; namely all calculations have been per-
formed using the population data and disease statistics 
for Germany.
One new feature of the tool is a full mathematical treat-
ment of uncertainties in the calculated risks, so that the risks 
can now be given with confidence intervals. Although Ger-
man population data are considered here for illustration of 
the dose to risk conversions, the software tool also incorpo-
rates data for four Nordic countries and Switzerland and can 
be routinely extended with data for other countries.
It is this new software tool, which has been applied for 
the calculations presented here to show how the dosimet-
ric limits can translate into cancer risk estimates and risk 
uncertainty. It is shown here that any one particular refer-
ence dose limit will translate differently into risks from sto-
chastic effects depending on age at exposure, gender, the 
“at-risk” time-frame considered and cancer risk type. The 
potential of risk assessment tools that have been fully devel-
oped and ready for operation, before any nuclear accident 
actually takes place, is discussed here along with the idea to 
incorporate such a tool into currently available dosimetric 
large-area monitoring systems, e.g., the Java-based real-time 
on-line decision support system (JRODOS) (Ehrhardt and 
Weis 2000; Ievdin et al. 2010). The JRODOS system has 
been developed for general application worldwide for use 
in national or regional nuclear emergency centres. JRODOS 
provides coherent support at all stages of an accident (i.e., 
before, during and after a radiological release), including 
the long-term management and restoration of contaminated 
areas. The system is able to support decisions about the 
introduction of a wide range of potentially useful counter-
measures (e.g., sheltering and evacuation of people, dis-
tribution of iodine tablets, food restrictions, agricultural 
countermeasures, relocation, decontamination, restora-
tion, etc.) mitigating the consequences of an accident with 
respect to detrimental health effects, the environment, and 
the economy. JRODOS can be applied to accidental releases 
into the atmosphere and into various aquatic environments. 
Appropriate interfaces exist with local and national radio-
logical monitoring data, meteorological measurements and 
forecasts, and for adaptation to local, regional and national 
conditions.
Detailed discussions are provided on how such risk 
information, including the relevant uncertainty of this risk 
information, could potentially be useful for integrating into 
the radiation protective decision making processes after a 
nuclear accident.
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Materials and methods
Radiation-related cancer risks were estimated for both 
males and females initially exposed as infants (age 1 year), 
children (age 10 years) or adults (age 20 years). Models 
for specific cancer sites were applied to calculate risks 
attributable to radiation over a lifetime and over the ini-
tial 20 years after the nuclear accident, based on generic 
recommended reference limits of effective dose converted 
to organ/tissue dose, and using demographic and health 
statistics data from a contemporary illustrative European 
population (German population).
Effective dose conversion to organ/tissue dose
Current IAEA safety requirements in their parts 3 and 7 
(IAEA 2014, 2015) give generic criteria for use in con-
junction with the goals of emergency response in terms of 
effective dose in the range 20–100 mSv, acute or annual, 
that includes dose contributions via all exposure pathways.
The ICRP has expressed caution in the use of effec-
tive dose for purposes of estimating risks to individuals 
or populations exposed to ionising radiation, especially 
for very heterogeneous exposures in medical procedures 
and environmental or occupational exposure to, for exam-
ple, radioisotopes of iodine (International Commission on 
Radiological Protection 2007, paragraph 151). Therefore, 
in order to calculate the risks corresponding to these IAEA 
reference levels of 100 mSv, acute or annual, in the urgent 
phase and an effective dose of 20 mSv per year in the 
transition phase it is necessary to convert these levels into 
organ/tissue doses for each of the target organs for the 
types of cancers evaluated (i.e., colon, red bone marrow, 
thyroid and breast organ/tissue doses for all solid cancer, 
leukaemia, thyroid and breast cancer, respectively).
A methodology that can be applied to calculate organ 
doses from effective doses for the general population has 
already been presented (WHO 2013, Annex G, p. 133). In 
this WHO methodology the organ dose coefficients have 
been deduced using relationships between effective and 
organ doses for age-dependent gender-specific human 
models (phantoms) exposed to external sources of low-
LET radiation (photons) presented by Jacob et al. (1990), 
Petoussi-Henss et al. (2012) and Saito et al. (2012). In an 
emergency situation, the organ doses could result from 
four possible pathways: (a) external exposure to radioac-
tive materials deposited on the ground; (b) external expo-
sure to the release plume or radioactively contaminated 
ambient air; (c) internal exposure due to inhalation of radi-
oactively contaminated air; and (d) internal exposure due 
to ingestion of radionuclides. The relative contributions 
to the total organ doses via each of these four pathways 
will be highly variable and dependent on the nature of 
the accident, peculiarities of radioactive contamination of 
the environment and human habitats, protective actions 
taken or other factors; therefore, no generic solution can 
be found without consideration of the specific exposure 
scenario.
In order to illustrate the principle of general consideration 
of risk bases for decision making, a simplifying assump-
tion is made here that either an acute or annual (first-year) 
effective dose just comes from external exposures to gamma 
radiation under a scenario equivalent to that realised after 
the Fukushima accident (the limitations of such an important 
assumption are fully given in the discussion section). Under 
this assumption, only external exposure to low-LET radia-
tion (photons and electrons with radiation weighting factor 
equal to one) is relevant and the organ absorbed doses (Gy) 
are numerically equal to the organ equivalent doses (Sv). 
The latter have been deduced from the effective dose in the 
WHO 2013 Report (see WHO 2013, Annex G, Table 19, p. 
134) and are used in this paper.
For the radionuclide composition specific to the Fuku-
shima accident, the deduced ratios of the organ and effective 
dose are very close to one, spanning the range from 0.89 
(adult, red bone marrow) to 1.0, so uncertainty associated 
with conversion of the effective dose coefficients is gener-
ally low, where external gamma radiation exposures are con-
cerned, under this scenario. The UNSCEAR 2013 Report 
has applied a similar approach using data from the ICRP 
Publication 74 (ICRP 1996) and the more recent results of 
Petoussi-Henss et al. (2012) and arrived at similar results: 
all differences between age-dependent organ absorbed and 
effective doses did not exceed 5–10% (UNSCEAR 2014, 
Attachment C-12).
Health statistics data
Population cancer incidence and mortality rates, given by 
sex, cancer site and 5-year age group, for 2014, are avail-
able from the German cancer register (RKI-GEKID 2017). 
All-cause mortality rates for 2013/2015 and general survival 
data from life tables for Germany are available from the 
German Federal Office for Statistics (Statistisches Bunde-
samt 2016). Similar data are already included for Denmark, 
Finland, Norway, Sweden and Switzerland.
Risk models for specific cancer sites
The following malignant diseases or groups of malignant 
diseases were considered (ICD-10 classification codes are 
shown in parentheses):
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• All solid cancers (C00–C80);
• Leukaemia, defined here as all leukaemia (i.e., most of 
the ICD10:C91–C95 subclasses, excluding CLL, C91.1 
and C91.4, and excluding ATL, C91.5);
• Female breast cancer (C50);
• Thyroid cancer (C73).
These groupings have been demonstrated to show a radia-
tion risk effect modification by age-at-exposure (UNSCEAR 
2013). The grouping “all solid cancer” (ICD10:C00–C80) 
was included to address the overall cancer risk from radia-
tion, because radiation can cause cancer in most organs/tis-
sues of the body, and to provide risk estimates based on a 
large outcome grouping with a higher statistical power than 
otherwise obtainable just from analyses on individual cancer 
sites. The group of leukaemia, including all types of leukae-
mia without CLL and without ATL, referred to hereafter 
as “leukaemia”, was considered due to their known radia-
tion sensitivity and short latency period, thus potentially 
becoming one of the first effects to be observed following 
radiation exposure. Significant increases in the number of 
thyroid cancers following exposure in childhood was shown 
as a major radiological consequence of the Chernobyl acci-
dent, so thyroid cancer is also considered here (UNSCEAR 
2008, Vol. II, Annex D). Breast cancer is the most common 
female cancer worldwide and is a leading cancer mortality 
cause among women. Breast tissue is also considered to be 
particularly radiosensitive at young ages at exposure, so the 
effect of radiation exposure on this type of cancer should 
also be considered.
The models of radiation risk, establishing relationships 
between the risk for the cancer type groupings given above and 
dose from exposure, were taken from publications related to 
the Japanese A-bomb survivor Life Span Study (LSS) cohort 
(the basis for this selection is given in the discussion section). 
These risk to dose response models are in terms of excess 
relative risk (ERR) and/or excess absolute risk (EAR) with 
the following: a follow-up 1958–2001 taken from Table 3 
of Hsu et al. (2013) (i.e., models for the grouping leukaemia 
minus CLL and minus ATL, based on 312 cases); a follow-up 
1958–1999 taken from Tables S2 and S3 of Jacob et al. (2014), 
for thyroid cancer; a follow-up 1958–2009 taken from Table 5 
of Grant et al. (2017), for all solid cancers unadjusted for 
smoking (although Grant et al. 2017 did not publish an EAR 
model unadjusted for smoking that would have been suitable 
for this application—the authors have provided such a model 
in “Appendix”). The model for breast cancer was taken from 
a pooled study of eight cohorts, i.e., the model in Table 12 of 
Preston et al. (2002), with the full parameter set given in Jacob 
et al. (2017), where the LSS cohort contributes almost 60% 
of cases. All these models have similar properties: a linear 
dose–response function for all solid cancers, thyroid cancer 
and female breast cancer and a linear-quadratic dose–response 
function for leukaemia; including risk effect modification by 
age-at-exposure (e), sex (s) and attained age (a).
To at least partially account for uncertainty associated 
with model selection, the Multi-Model Inference (MMI) 
technique (see, e.g., Burnham and Anderson 2002) was used 
wherever possible. Namely, for each of the two groupings all 
solid cancers (Grant et al. 2017) and leukaemia cancers (Hsu 
et al. 2013), two models, one of EAR-type and one of ERR-
type, were used for risk calculations with relative weights 
based on the Akaike Information Criterion (AIC) (as in 
Walsh and Schneider 2013). The EAR-type model of Preston 
et al. (2002) for breast cancer was developed from a pooled 
cohort and no updated alternative models were found for this 
pooled cohort at the time of writing. The thyroid cancer risk 
model of Jacob et al. (2014) was of ERR-type. The excess 
and baseline incidence rates provided by the risk models 
are pertinent to their respective epidemiological cohort—for 
the considered models, this is mainly the LSS cohort. To 
estimate radiation risks for the target population, i.e., popu-
lation of interest, these rates need to be “transferred”, which 
means that the estimated radiation-attributed excess rate is 
transformed using the ratio of the model and the population 
baseline rates assuming either additive (the same EAR) or 
multiplicative (the same ERR) mechanisms of transfer. More 
on this procedure can be found in Ulanowski et al. (2016).
Following risk transfer, the resulting excess incidence rate, 
ER(d, e, a, s) , is given by
where f is the weighting factor between an additive (EAR) 
and a multiplicative (ERR) transfer of risk; m(a, s) is the 
age- and sex-specific baseline cancer incidence rate in the 
target population. To allow for modelling uncertainty asso-
ciated with unknown type of risk transfer mechanism the f 
values were part of the Monte Carlo simulation procedure 
with the sampling distribution assumed to be uniformly dis-
tributed in the range from 0 to 1.
For breast cancer, where only an EAR-type model was 
applied, as strongly recommended by Preston et al. (2002), 
the risk transfer was modelled assuming an unknown ratio of 
baselines in epidemiological cohorts and the target populations 
(see details in Ulanowski et al. 2016). For thyroid cancer, the 
risk transfer was modelled based on only an ERR model, as 
described in Jacob et al. (2014).
Computations in this paper have been performed using con-
temporary cancer incidence rates for an illustrative European 
population (Germany) in 2010–2014.
Risk quantities
The conventional lifetime attributable risk (LAR) (Thomas 
et al. 1992; Vaeth and Pierce 1990) was selected as the risk 
(1)
ER(d, e, a, s) = f EAR(d, e, a, s) + (1 − f )ERR(d, e, a, s)m(a, s),
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quantity for application here. LAR closely approximates the 
risk of exposure-induced death from (REID) or incidence of 
(REIC) cancer, and other similar measures (Kellerer et al. 
2001), at the doses relevant to protecting populations from 
stochastic effects following exposures with organ doses under 
about 0.5 Gy.
The central estimate for the attributable risk from either 
one annual dose or one acute dose, AR(d, e, s, a) , specifies 
the sex (s) and age-at-exposure (e) specific cumulative prob-
ability of a specific cancer attributable to radiation exposure 
with dose d. The AR involves integrating over time, t, from 
e up to an age a:
Here d is the dose delivered to the organ/tissue at age-
at-exposure e, and FL(a − e) is a function smoothly varying 
from 0 to 1 which models the effects of the unknown mini-
mum latent times between the delivery of the dose to the 
organ and the expression of the radiation-related cancer risk.
If the integration of the risk is performed over the whole 
lifetime, then Eq. (2) converges to a conventional definition 
of LAR:
The latency function, FL , for all solid cancers, includ-
ing breast and thyroid cancers, grow from zero to one in the 
range, approximately, from 1.5 to 7 years since exposure, 
while reaching the value 0.5 at time 3.5 years since expo-
sure (where these values were chosen with a consideration of 
recommended values (UNSCEAR 2008, BEIR VII—Phase 
2 2006, Heidenreich 1999). For leukaemia, the minimum 
latency period is shorter, and the corresponding latency func-
tion grows from 0 to 1 in the range from 1 to 3 years since 
exposure, while having the value of 0.5 at time 1.5 years after 
exposure (again values were chosen to be consistent with 
recommended values (UNSCEAR 2013, Annex B)).
T h e  c o n d i t i o n a l  s u r v i v a l  c u r v e 
Saj(t|e, s) = Saj(t, s)∕Saj(e, s) , is the probability of surviv-
ing cancer-free to age t conditional on the probability to 
be alive and disease-free at the age of exposure e. Saj(t|e, s) 
was calculated from the German life tables as well as cause-
specific incidence and mortality rates in 2014, as described 
above. LAR or AR was also compared with the lifetime or 
age-specific baseline risk (LBR or BR, correspondingly) in 
order to put radiation-related cancer risks into the perspec-
tive of the baseline cancer risk in Germany (i.e., the risk in 
the absence of radiation exposure from an accident). Apply-
ing the same notation as for definition of AR (Eq. 2), the BR 
and LBR conditional on disease-free survival to age e are 
calculated as follows:








(3)LAR(d, e, s) = AR(d, e, s,∞).
The duration of any lifetime segment at-risk considered 
depends on the age at exposure (i.e., the higher the ages at 
initial exposure the shorter the lifetime segment up to old 
age). This causes any comparisons of results among different 
ages at exposure to be complicated. Therefore, the cumu-
lative risks over 20 years-at-risk after the initial exposure 
 (AR20,  BR20) were also calculated.  AR20 can be a suitable 
representation to satisfy interest in early risks of cancer from 
a short-term public health perspective and also for compari-
sons between calculated risks and risks potentially provided 
by any epidemiological studies initiated after an emergency. 
 AR20 is particularly relevant for cancer types such as leukae-
mia and thyroid cancer where the relative increase in risk 
is expected to be stronger during the first few decades after 
exposure during childhood. It is pertinent to note that these 
risk quantities, although they can be based on individual 
doses, cannot represent an individual’s risk due in-part to a 
lack of knowledge on other individual risk factors (see dis-
cussion). The forms given in the Eqs. (2)–(4), which result in 
probability values for the various risk measures, are, there-
fore, more appropriate to consider in the results section, when 
simply converted into number of cases per 10,000 persons.
Treatment of uncertainties in the risk calculations
Such lifetime risk estimates are associated with large uncer-
tainties that were quantified here with stochastic simulation 
following a methodology that has recently been described 
for non-time-integrated risks (Ulanowski et al. 2016) and 
time-integrated thyroid cancer risks (Jacob et al. 2014, with 
full details in the supplementary material for this cited refer-
ence). The following uncertainties were included here in the 
simulation of overall risk uncertainties:
1. The radiation risk model parameters from the A-bomb 
LSS cohort and the pooled breast cancer cohorts were 
sampled from a multivariable normal distribution using 
best estimates of all the model parameters, including 
parameters specifying baseline incidence in the LSS 
cohort, and the respective full covariance matrices.
2. The transfer factors f (i.e., from Eq. 1, for apportioning 
additive and multiplicative radiation risk contributions) 
were sampled from a uniform distribution: f ∼ U(0, 1) , 
thus corresponding to highest uncertainty of risk transfer.
3. Dose rate effects were sampled from a lognormal dis-
tribution with a geometric mean of 1.0 and geometric 
standard deviation varying as a linear function of dose 
rate (Jacob et al. 2014, 2017) with value of 1.5 at dose 
(4)




m(t, s)Saj(t|e, s)dt and LBR(e, s) = BR(e, s,∞).
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rate 1.5 mGy day−1 and value of 1 at dose rate equal to 
or higher than 6 mGy h−1. Correspondingly, the median 
dose rate correction factor does not change but results 
in a higher variance at lower dose rates.
4. The minimum latency periods were sampled from a sig-
moid distribution with parameters suggested by I. Apos-
toaei (ORRISK, USA) and found in Jacob et al. (2017).
5. Uncertainty of incidence data was sampled from Poisson 
distributions of the reported number of cancer cases in a 
country in the corresponding 5-year age interval.
6. The doses were sampled from a log-normal distribution, 
with arithmetic means of 20 and 100 mSv (converted 
into organ doses appropriate to the cancer outcome type 
considered, Table 1). The geometric standard deviations 
were assumed here to be 1.5 (see, e.g., Harada et al. 
2014) and the arithmetic mean organ dose values were 
converted to geometric means to account for the known 
inequality between these two quantities.
Results
Table 1 gives the organ dose ranges corresponding to an 
effective dose range of 20–100 mSv, calculated with the 
ratios of organ to effective dose from external exposures, 
taken from Table 19 of the WHO report (2013, Annex G, 
p. 134).
The LAR, LBR,  AR20 and  BR20 risks (i.e., integrated over 
lifetime and the first 20 years at-risk since exposure) which 
have been simply converted from probabilities to numbers of 
excess cases and number of baseline cases per 10,000 persons, 
for age at exposure 1, 10 and 20 years, are given in Tables 2, 
3, 4 and 5, and Figs. 1, 2, 3 and 4, for all solid cancers, leukae-
mia, thyroid and female-breast cancers, respectively.
Considering the risk of all solid cancers (Table 2 and 
Fig. 1), it can be seen that adult females have a larger radia-
tion risk than adult males, over the first 20 years-at-risk since 
exposure and over lifetime, but male adults have a lower 
baseline risk over the first 20 years-at-risk since exposure, 
but a higher lifetime baseline risk than females. For children 
and infants, the lifetime and 20-year radiation risk is higher 
for females than for males. Given that the grouping “all solid 
cancer” will provide risk estimates with higher statistical 
power than obtainable with individual cancer sites it is note-
worthy that the 95% confidence intervals on the numbers of 
cases expected per 10,000 persons at 100 mSv over lifetime 
are still large, e.g., 416 (95% CI 164; 1200), 350 (95% CI 
149; 895) and 257 (95% CI 112; 618) for females exposed 
as infants, children and adults, respectively.
Table 1  The organ dose ranges corresponding to an effective dose 
range of 20–100 mSv, calculated with the ratio of organ to effective 
dose, from external exposures, for the situation after the Fukushima 
accident, as given in Table 19 of the WHO report (2013, Annex G, 
p. 134)
Age at exposure 
(year)
Organ dose ranges (mSv) corresponding to an effec-
tive dose range of 20–100 mSv
Breast Colon RBM Thyroid
20 (adult) 19.8–99 18.2–91 17.8–89 20–100
10 (child) 20–100 19.2–96 20–100 20–100
1 (infant) 20–100 18.2–91 18.8–94 20–100
Table 2  All solid cancer, ranges 
for median number of cases per 
10,000 persons after 20 years 
and during lifetime based on 
German population data for 
20–100 mSv effective dose 
range
All of the tabulated results come from Monte-Carlo simulations and are, therefore, subject to statistical 
fluctuations
Ranges for median numbers of cases per 10,000 (with 95% CI) after 
20 years-at-risk since exposure and during lifetime simply converted 





Effective dose 20 mSv 100 mSv 20 mSv 100 mSv
20 (adult) AR20 2 (1; 14) 11 (3; 70) 5 (2; 13) 25 (10; 63)
LAR 33 (15; 76) 166 (73; 381) 51 (22; 123) 257 (112; 618)
BR20 102 (90; 116) 164 (149; 181)
LBR 4005 (3878; 4140) 3509 (3385; 3639)
10 (child) AR20 2 (0; 40) 10 (2; 200) 3 (1; 9) 17 (6; 43)
LAR 46 (18; 143) 229 (92; 716) 70 (30; 179) 350 (149; 895)
BR20 45 (37; 54) 50 (42; 60)
LBR 4002 (3873; 4140) 3509 (3383; 3643)
1 (infant) AR20 1 (0; 29) 5 (0; 144) 2 (1; 8) 11 (3; 41)
LAR 53 (18; 219) 264 (88; 1097) 83 (33; 240) 416 (164; 1200)
BR20 20 (14; 27) 18 (13; 26)
LBR 4002 (3871; 4143) 3511 (3383; 3647)
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The trends apparent from Table 3 and Fig. 2 for leukae-
mia, in the radiation risk sex differences, reflect those differ-
ences reported in the ERR and EAR LSS risk models (Hsu 
et al. 2013), i.e., the ERR model did not support a gender 
effect but the EAR did, with a female to male ratio of 0.66. 
Due to the equal probability of additive and multiplicative 
transfer types in the LAR calculations applied here, it can 
be seen that the male radiation risks are consistently slightly 
higher than the female risks at the same doses and for all 
ages at exposure considered. The male leukaemia baseline 
risk over the first 20 years-at-risk since exposure and over 
lifetime are also consistently higher than the female risks 
for all three ages at exposure considered. It can also be seen 
from Table 3, by comparing the numbers of cases per 10,000 
persons after 20 years-at-risk since exposure with the num-
bers of cases per 10,000 during lifetime, that a substantial 
proportion of the overall radiation risk is accumulated in the 
first 20 years-at-risk since exposure: for adults and children, 
Table 3  Leukaemia, ranges for 
median number of cases per 
10,000 persons after 20 years 
and during lifetime based on 
German population data for 
20–100 mSv effective dose 
range
All of the tabulated results come from Monte-Carlo simulations and are, therefore, subject to statistical 
fluctuations
Ranges for median numbers of cases per 10,000 (with 95% CI) after 
20 years-at-risk since exposure and during lifetime simply converted 




Effective dose 20 mSv 100 mSv 20 mSv 100 mSv
20 (adult) AR20 1 (0; 3) 4 (0; 14) 0 (0; 2) 2 (0; 11)
LAR 2 (0; 7) 10 (0; 35) 1 (0; 5) 7 (0; 29)
BR20 7 (4; 11) 5 (3; 8)
LBR 153 (129; 184) 112 (92; 138)
10 (child) AR20 1 (0; 6) 6 (0; 33) 1 (0; 5) 4 (0; 29)
LAR 2 (0; 11) 13 (0; 62) 2 (0; 10) 10 (0; 57)
BR20 7 (4; 11) 4 (2; 8)
LBR 156 (131; 190) 115 (94; 143)
1 (infant) AR20 3 (0; 25) 19 (0; 138) 2 (0; 20) 14 (0; 112)
LAR 6 (0; 33) 30 (1; 176) 4 (0; 28) 22 (0; 148)
BR20 9 (6; 14) 7 (4; 12)
LBR 161 (134; 197) 119 (96; 149)
Table 4  Thyroid cancer ranges 
for median number of cases per 
10,000 persons after 20 years 
and during lifetime based on 
German population data for 
20–100 mSv effective dose 
range
All of the tabulated results come from Monte-Carlo simulations and are, therefore, subject to statistical 
fluctuations
Ranges for median numbers of cases per 10,000 (with 95% CI) 
after 20 years-at-risk since exposure and during lifetime simply 
converted (10,000 times risk) from the risks in column 2
Age at exposure 
(years)
Sex Male Female
Effective dose 20 mSv 100 mSv 20 mSv 100 mSv
20 (adult) AR20 0 (0; 1) 1 (0; 3) 0 (0; 2) 2 (0; 9)
LAR 1 (0; 2) 3 (0; 11) 2 (0; 6) 9 (2; 28)
BR20 5 (3; 9) 19 (14; 25)
LBR 32 (22; 48) 77 (61; 101)
10 (child) AR20 0 (0; 1) 1 (0; 4) 0 (0; 2) 2 (0; 10)
LAR 1 (0; 4) 5 (1; 21) 4 (1; 11) 20 (6; 56)
BR20 2 (1; 5) 8 (5; 12)
LBR 32 (22; 49) 78 (61; 103)
1 (infant) AR20 0 (0; 1) 1 (0; 5) 0 (0; 1) 2 (0; 7)
LAR 2 (0; 9) 9 (1; 43) 8 (2; 27) 41 (11; 133)
BR20 1 (0; 2) 2 (1; 4)
LBR 32 (22; 50) 78 (61; 104)
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just under half of the lifetime risk from 100 mSv is accu-
mulated in the first 20 years-at-risk; and for infants about 
two-thirds of the lifetime risk from 100 mSv is accumulated 
in the first 20 years-at-risk.
Considering the risks for thyroid cancer given in Table 4 
and Fig. 3, it can be seen that females have higher radiation 
risks at the same dose and higher baseline risks than males. 
The numbers of cases expected per 10,000 at 100 mSv over 
lifetime is 41, 20 and 9 for females exposed as infants, chil-
dren and adults, respectively. The numbers of cases expected 
per 10,000 at 100 mSv over lifetime is 9, 5 and 3 for males 
exposed as infants, children and adults respectively. How-
ever, it can be seen from Table 4 and Fig. 3 that the uncer-
tainties on these expected numbers of cases are large.
Table 5 and Fig. 4 show, for female breast cancer, that 
the numbers of cases expected per 10,000 for an exposure 
of 100 mSv over lifetime is 173, 109 and 65 for exposure as 
infants, children and adults, respectively.
Compared to the numbers of cases for female all solid 
cancers expected per 10,000 at 100 mSv over lifetime of 
416, 350 and 257 for exposure as infants, children and 
adults, respectively—the breast cancer risk represents a sub-
stantial fraction of the total all solid cancer risk. This feature 
of the results can also be seen from Fig. 5 which shows 
the expected number of cases per 10,000 persons for differ-
ent types of cancer, calculated from the LAR for 100 mSv 
effective dose for age at exposure of 1 year. From Fig. 5 it 
can also be seen that in absolute terms, the risks for thyroid 
cancer and leukaemia are much smaller than for all solid 
cancer and female breast cancer.
Discussion
In the past, cancer risk assessment software was not 
designed to be fully developed and ready for operation, 
before a nuclear accident actually took place. Therefore, 
after the Fukushima nuclear accident in March 2011 there 
was no suitable software available for immediate use. The 
Table 5  Breast cancer ranges for median number of cases per 10,000 
persons after 20 years and during lifetime based on German popula-
tion data for 20–100 mSv effective dose range
All of the tabulated results come from Monte-Carlo simulations and 
are, therefore, subject to statistical fluctuations
Ranges for median numbers of cases per 10,000 (with 
95% CI) after 20 years-at-risk since exposure and dur-
ing lifetime simply converted (10,000 times risk) from 




Effective dose 20 mSv 100 mSv
20 (adult) AR20 1 (0; 3) 4 (1; 14)
LAR 13 (4; 42) 65 (20; 211)
BR20 53 (45; 62)
LBR 1235 (1161; 1313)
10 (child) AR20 0 (0; 2) 2 (1; 8)
LAR 22 (7; 69) 109 (34; 345)
BR20 7 (5; 10)
LBR 1234 (1160; 1312)
1 (infant) AR20 – –
LAR 35 (10; 113) 173 (51; 566)
BR20 0 (0; 1)
LBR 1232 (1159; 1310)
Fig. 1  Male and female all solid cancer baseline (dark grey) and radiation (light grey with error bars) risks in cases per 10,000 persons calcu-
lated from LBR and the LAR for 100 mSv effective dose. Error bars are for 95% confidence intervals
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time intervals between the Fukushima nuclear accident on 
11th March 2011 and the publication of various interna-
tional health risk assessments, such as those from the WHO 
(2013) or UNSCEAR (2014), of just under 2 years and just 
over three and a half years, respectively, is illustrative of 
this situation. Such long time intervals are generally due to 
the work-load, after the event, in assembling expert groups, 
assessing doses, developing a risk assessment framework 
and developing the risk assessment software.
There is, therefore, a great potential for risk assess-
ment tools that have been fully developed and are ready for 
operation, before any nuclear accident actually takes place. 
The probability for such an accident to happen in the next 
decades is not negligible (Kaiser 2012). Such potential 
is even greater, if the risk assessment tools can be either 
directly integrated into, or used in tandem with, currently 
available dosimetric large-area monitoring systems (e.g., 
JRODOS, Ehrhardt and Weis 2000; Ievdin et al. 2010).
JRODOS so far provides only dose-based results as input 
to the decision making process. Doses might be either based 
on prognostic calculations applying an estimated source 
term and numerical weather prognosis data or on available 
Fig. 2  Male and female leukaemia baseline (dark grey) and radiation (light grey with error bars) risks in cases per 10,000 persons calculated 
from LBR and the LAR for 100 mSv effective dose. Error bars are for 95% confidence intervals
Fig. 3  Male and female thyroid cancer baseline (dark grey) and radiation (light grey with error bars) risks in cases per 10,000 persons calculated 
from LBR and the LAR for 100 mSv effective dose. Error bars are for 95% confidence intervals
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monitoring information. The monitoring information is point 
based but, within the EU-CONFIDENCE project, interpo-
lation schemes are under development to provide aerial 
information from the prognostic calculations. However, as 
discussed above, risk-based assessments are important for 
estimating health effects and deciding on interventions, e.g., 
on medical screening actions. Effective medical screening 
has to be initiated early after the emergency and thus risk-
based approaches, complementary to monitoring and prog-
nosis results, will improve the potential in decision making.
In providing a framework and a software for use in health 
risk assessment, it is important to stress the necessity of 
avoiding any misunderstandings in the interpretation of the 
risks calculated. Risks in terms of lifetime attributable risks, 
LAR, calculated here, although they could be based on indi-
vidual doses, cannot represent an individual’s cancer risks. 
This is because there is generally no information on impor-
tant co-factors that influence a particular individual’s cancer 
risk such as the following: individual radiation sensitivity; 
any genetic pre-disposition to cancer development; lifestyle 
factors such as smoking status and alcohol intake; occu-
pational risk factors; and past medical conditions treated 
with chemotherapy or radiation. Furthermore, population-
based incidence and survival curves, used in the integra-
tion of risks over time, only represent average values for 
the national population considered. With all of these factors 
considered, LAR and  AR20 should, therefore, be interpreted 
as an average risk for specific ages at exposure and genders. 
So, for example, an all solid cancer incidence LAR of 0.0264 
(probability) for a male exposed to 100 mSv at age 1 year, 
should not be interpreted as an individual’s risk, but must 
be seen statistically—out of 10,000 males exposed at age 
1 year to 100 mSv effective dose, there is a probability that, 
on average, 264 (note the wide 95% confidence intervals 
ranging from 88 to 1097) will develop radiation-related solid 
cancer during their lifetimes—and on average, 4002 will 
develop baseline cancers during their lifetimes. These risks, 
computed using the procedure defined above, are mathemati-
cal expectations of the number of new radiation-attributed 
and baseline cases. Their uncertainty ranges (CIs) reflect 
the uncertainties of the estimates as listed in the “Methods” 
section. The number of cases observed in future would have 
additional sources of variability (uncertainty), dependent 
on, e.g., the size of the population group, or future devel-
opments in the secular trends in population statistics (on 
which the risks are based) which are not accounted for here. 
Further work is currently being done on methods that reduce 
the dependence, of radiation related risk assessments, on 
population statistics and survival curves (Ulanowski et al. 
2019), which is particularly useful for risk assessments in 
highly atypical exposed groups (e.g., astronauts, see Walsh 
et al. 2019). A further source of uncertainty, not directly 
accounted for here, is related to the basis for the selection 
of the risk to dose response models applied here in the cal-
culation of lifetime risks. These risk models, mostly from 
the LSS with publicly available data, are all recent, but a 
constraint on this selection comes from the requirement to 
have the full covariance matrix for the models applied here 
to do the uncertainty analysis. This means that access to 
the original data is required so that the covariance matrices 
(not usually published in papers with risk model parameters) 
can be obtained when new publications become available. A 
further consideration of multi-model inference using other 
published models is, therefore, for this reason, a major 
undertaking and is a suggestion for future work.
In developing the risk assessment framework applied 
in the WHO Fukushima Health Risk Assessment Report 
Fig. 4  Female breast cancer baseline (dark grey) and radiation (light 
grey with error bars) risks in cases per 10,000 persons calculated 
from LBR and the LAR for 100 mSv effective dose. Error bars are for 
95% confidence intervals
Fig. 5  Cases per 10,000 persons for females (light grey) and males 
(dark grey) for different types of cancer, calculated from the radiation 
risks, LAR for 100 mSv effective dose for age at exposure of 1 year. 
Error bars are for 95% confidence intervals
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(WHO 2013), the WHO expert panel considered that risk 
assessment should be based on a comprehensive assessment 
of all current evidence from all of radiation epidemiology 
and not only on the epidemiological evidence available from 
past nuclear accidents such as Chernobyl. Similarly, the 
authors consider that the risk assessment framework applied 
in the software tool described here, should also be based 
on comprehensive assessment of all current evidence from 
radiation epidemiology. There are several disadvantages to 
considering only radiation epidemiological evidence from 
past nuclear accidents. Many of these studies have risks that 
are compatible with risks from other types of studies (e.g., 
Thyroid cancer risks in post-Chernobyl studies and the LSS 
studies, see, e.g., Figure 4 of Jacob et al. 2014)—so other 
types of studies can provide added weight of evidence to 
risk-levels determined from post nuclear accident studies. 
Generally, the ecological study designs that can be applied 
after nuclear accidents, are not as reliable as other cohort-
type study designs applied in other types (e.g., occupational) 
of studies. Also there have been several meta-analytical stud-
ies looking into the effects of low-dose and low dose rates on 
cancer risks from a broad range of epidemiological studies 
(e.g., Shore et al. 2017), evidence from studies such as these, 
would be ignored, if only studies from past-nuclear accidents 
were considered.
In order to simplify and illustrate this general considera-
tion of applying risk bases for decision making, it is assumed 
here that either an acute or annual (first-year) effective dose 
just comes from external exposures in a situation compa-
rable to the Fukushima release. Although exposures to 131I 
occurred in this release, the total thyroid dose ranges were 
much lower and much narrower than the ranges in either the 
LSS or after Chernobyl. Furthermore considering the risk 
contribution from internal and external thyroid exposures, 
the thyroid cancer incidence ERR after external exposure 
during childhood to a thyroid dose of 1 Sv in the LSS is very 
similar to study results of populations exposed to 131I after 
the Chernobyl accident (e.g., see the Fig. 4, upper panel in 
Jacob et al. 2014). In real life emergency situations the rele-
vant exposure pathways should include internal exposure via 
inhalation and ingestion pathways. The total dose delivered 
during the acute period can be dominated by various sources 
depending on weather conditions, release and fallout proper-
ties and isotopic composition, and on countermeasures, such 
as evacuation or distribution of stable iodine. Total doses 
accumulated during longer time periods are more likely to 
have larger contributions from external exposure. Unfold-
ing the effective dose coefficients back to organ doses (as 
shown in Table 1) is easier to apply for external exposure; 
therefore, external exposures are considered here for illus-
trative purposes. Organ doses for internal exposures cannot 
be deduced from the effective dose coefficients as straight-
forwardly as for external exposure, because, by definition, 
the effective dose coefficient is a committed effective dose 
per unit intake of the parent radionuclide integrated for 
50 years after intake, which takes into account retention of 
the taken radionuclide and its radioactive progeny in the 
body. Though, in many practical situations for radionuclides 
with short effective half-life or residence time, such as radio-
active isotopes of iodine or caesium, such unfolding can be 
still reasonably achieved (see, e.g., procedure described in 
United Nations Effects of Ionizing Radiation 2014, Attach-
ment C-12 and WHO 2013 pp. 134–135, Tables 20 and 21). 
For radionuclides with long residence time or isotopes of 
bone-seeking elements (90Sr, actinides) such an unfolding 
may be regarded as implausible and more direct methods of 
evaluating the organ doses from exposure to such radionu-
clides need to be applied.
If decisions have to made in the emergency phase of an 
accident, and radionuclides such as 131I are released, then 
various parts of the human body are inhomogeneously 
exposed and organ doses may vary considerably. For such 
exposure situations, translation of effective dose to organ 
dose can be achieved only for a specific exposure scenario 
by considering exposure pathways, intake and inhalation, 
age, sex, diet, location and occupation factors for specific 
population groups or individuals. However, the aim here was 
to illustrate how risk bases can be applied to complement 
decision making based on dose bases, not necessarily to 
reproduce fully realistic post-accident dosimetric situations 
which will depend heavily on the type of accident and local 
conditions at the time of the accident and immediately fol-
lowing. Further work is required to refine the calculations of 
organ doses from internal exposures that can cause problems 
in the early stages of a nuclear accident.
In deciding on the types of uncertainties to apply to the 
dosimetric reference levels, it should be considered that a 
reference level is an operational intervention level, above 
which, an action is taken. In that sense, reference levels 
are deterministic values, with no uncertainties per defini-
tion. The uncertainty in the decision making is introduced 
by comparing assessed or measured doses (that do have 
uncertainty) with the reference level (without uncertainty). 
Consequently, an uncertainty has been assigning here to the 
reference levels in order to consider the uncertainty in the 
actually assessed doses. The question then is, whether these 
assessed doses are log-normally distributed or normally dis-
tributed. On the one hand, measured doses for an individual 
(e.g., thyroid absorbed dose) could be expected to follow a 
normally distributed error, but doses calculated from simula-
tions and estimated source term or assessed from monitoring 
data could be better represented by log-normally distributed 
uncertainties. For the purpose of the main results given here, 
a log-normal distribution was applied with GSD = 1.5 (see, 
e.g.. Harada et al. 2014) but all tables were also calculated 
for a normal distribution with a SD which is 20% of the dose 
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reference level (these results tables are not shown). The dif-
ferences between the risk factors when calculated for both 
types of dose uncertainties were found to be quite small. As 
examples of this if one considers the all solid cancer num-
ber of lifetime cancers per 10,000 persons, from exposure 
to 100 mSv at 1 year (i.e., as given in Fig. 5), for males 
and females the values are 264 (88; 1097) and 416 (164; 
1200), respectively; these are 279 (119; 898) and 455 (224; 
975) respectively, when calculated assuming that dosimet-
ric errors follow a normal distribution with a SD which is 
20% of the dose reference level. In the calculations presented 
here, the dosimetric reference levels have been assumed to 
be at the centre of the dosimetric uncertainty treatment. In 
practice, the reference levels could pertain to maximum 
doses. In this situation, and based on real life dosimetric 
data, the CONFIDENCE tool could then be applied treating 
the dosimetric uncertainties with a realistic dose distribution 
with the reference levels taken to be the upper 90% or 95% 
confidence level of the dose distribution. Such an applica-
tion of the software tool will be considered for further work.
Although current radiological emergency response rec-
ommendations have been provided in safety standards and 
requirements published by the IAEA (2015) and based on 
the 2007 Recommendations of ICRP (2007), not all coun-
tries will adopt the recommendations exactly. Currently 
accepted dosimetric reference levels vary in different Euro-
pean countries. For example, the UK uses reference levels 
that are higher than recommended by IAEA of 30–300 mSv 
whole body dose for evacuation (Ashley et al. 2017). In Ger-
many, the national Commission on Radiological Protection 
(SSK 2014) has decided to adopt the 2007 ICRP recom-
mendations, and the IAEA safety requirements. Similarly, 
in Switzerland, the ICRP recommendations and the IAEA 
safety documents have been adopted (Swiss RPO, 2017—
Art 123).
Such differences in national currently accepted dosimet-
ric reference levels can broadly be translated linearly into 
risk differences, for the same dose metric, for the all solid 
cancer, breast cancer and thyroid cancer risks presented in 
this paper– because the LAR estimates are calculated from 
linear ERR and EAR models. However, the leukaemia LAR 
estimates would, strictly speaking, need to be recalculated 
for other reference doses due to the parabolic shape of the 
leukaemia cancer ERR and EAR dose response applied here 
(Hsu et al. 2013), but at low doses, the linear component of 
risk dominates and can, therefore, provide a good approxi-
mation of the risk. Based on current epidemiological data, 
the assumption of linearity in the risk to dose response for 
solid cancers (i.e., Linear Non-Threshold, LNT), appears to 
be the most practical and prudent choice for radiation protec-
tion purposes (NCRP 2018, Shore et al. 2018). Although the 
Grant et al. (2017) results for all solid cancer incidence in 
the LSS indicated that a linear-quadratic ERR dose response 
model fitted the male data better than the linear model, the 
linear models were applied in this work for consistency with 
current radiation protection guidelines based on LNT and 
the precautionary principle.
The results given in Tables 2, 3, 4 and 5 (and the Figs. 1, 
2, 3, 4, 5) show how reference dose levels can translate dif-
ferently into risks depending on age at exposure, gender, 
the length of the at-risk time-frame considered and can-
cer risk type. These results illustrate the potential for such 
risk-based information to be used by decision makers, in 
the urgent and transition phases of nuclear emergencies, to 
identify protective measures (e.g., sheltering, evacuation) 
in a differential way (i.e., for particularly susceptible sub-
groups of a population). For example, sensitive sub-groups 
of the population can be identified, such as children, for 
priority consideration. Application of nominal risks pro-
vided by ICRP 103 (2007) could in theory also be applied 
for this purpose, but due to the method of calculation, which 
involves averaging lifetime risks calculated in 5-year inter-
vals of age at exposure, over age at exposure and averaging 
over sex, differential risk information is lost. Also, the new 
software tool presented here may be applied with directly 
relevant population data for the geographical area at risk. 
Another advantage of applying risk-bases similar to those 
presented here is that they include realistic 95% confidence 
intervals, allowing decision makers to consider best case 
and worst-case scenarios, before implementing protective 
measures.
Table 6  Fit parameters for the LSS EAR model considered with the 
general form (d, e, a, s) = 0(e, a, s) + EAR(d, e, a, s) , where  is 
the total incidence rate, 0 is the baseline incidence rate, e is age at 
exposure, a is attained age (both in years), s is sex, d is the dose (Gy) 
delivered to the organ/tissue, i.e., colon dose, at age e 
All solid cancer
This model was fitted by the current authors using the dataset sol_
col_2017ext_v1.csv from http://www.rerf.or.jp, as recently applied (Grant 
et al. 2017)
EAR(d, a, e, s) = (1 + ts)kdd exp
(
−




Fit parameters with standard errors are:
t = 0.1385 ± 0.06223, kd = 53.31 ± 4.772, e = 0.03195 ± 0.005086, 

a
 = 2.350 ± 0.2097 (deviance = 57,405.1, df = 185,095)
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Conclusions
Due to long delays, in the past, between the occurrence of 
nuclear accident and the publications of relevant radiation-
related health risk assessments, it is useful to have a soft-
ware tool ready and available, before future accidents occur. 
The EU-CONFIDENCE tool, described here, is a software 
tool that can provide risk-based assessments (with uncer-
tainties) potentially important for estimating health effects 
from external exposures and deciding on interventions such 
as medical screening actions. Effective medical screening 
has to be initiated early after the emergency and so risk-
based results are recommended for consideration and to be 
complementary to monitoring and prognosis results. Such 
a joint consideration of risk bases and dose bases should 
improve the overall evidence bases on which important 
radiation protection decisions will need to be made after a 
nuclear accident.
Acknowledgements This project has received funding from the 
Euratom research and training programme 2014–2018 under grant 
agreement No. 662287. The EU-CONFIDENCE project is part of the 
CONCERT project. This paper makes use of data obtained from the 
Radiation Effects Research Foundation (RERF), Hiroshima and Naga-
saki, Japan. RERF is a public interest incorporated foundation funded 
by the Japanese Ministry of Health, Labour and Welfare (MHLW) and 
the U.S. Department of Energy (DOE). The data include information 
obtained from the Hiroshima City, Hiroshima Prefecture, Nagasaki 
City, and Nagasaki Prefecture Tumor Registries and the Hiroshima and 
Nagasaki Tissue Registries. The conclusions in this paper are those of 
the authors and do not necessarily reflect the scientific judgment of 
RERF or its funding agencies.
Disclaimer This publication reflects only the authors’ view. Responsi-
bility for the information and views expressed therein lies entirely with 
the authors. Neither the German Government nor the European Com-
mission nor the International Atomic Energy Agency are responsible 
for any use that may be made of the information it contains.
Compliance with ethical standards 
Conflict of interest None of the authors have any conflicts of interests 
relevant to the work contained in this paper.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
Appendix
Supplementary model fitting results are given here for the LSS 
all solid cancer incidence Excess Absolute Risk (EAR) risk 
model applied in the software tool. This was necessary because 
the original publication (for follow-up 1958–2009, Grant et al. 
2017) did not provide an EAR model without smoking adjust-
ment [i.e., an EAR model with the same adjustments as the 
ERR model given as the first entry in Table 5 of Grant et al. 
(2017)]. Such a model is analogous to the earlier EAR all solid 
cancer incidence model (for follow-up 1958–1998, Preston 
et al. 2007) that was found to be very appropriate for and used 
in the WHO Fukushima risk assessment (WHO 2013). The fit 
parameters (see Table 6) and parameter covariance matrix for 
this EAR model, unadjusted for smoking, were obtained using 
the publicly available data set (rerf.or.jp) and the EPICURE 
software with the AMFIT module (Preston et al. 1993) for Pois-
son regression on grouped data.
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